T he everolimus-eluting bioresorbable vascular scaffold (BVS, Abbott Vascular, Santa Clara, CA) is an exciting advance in percutaneous coronary intervention (PCI), providing a temporary coronary scaffold for at least 3 months and being resorbed by about 2 years. [1] [2] [3] Along with patient preference, potential advantages over metallic stents include restored vasomotion, reduced late thrombosis, and unimpaired imaging with computed tomography and magnetic resonance. However, advances in interventional devices may bring new challenges in the early days of the technology.
A 78-year-old man with recent-onset angina was enrolled in the ABSORB Trial Cohort B Group 1. 3 An obtuse marginal coronary artery branch measuring by quantitative angiography 3.5 mm upstream and 3.0 mm downstream from a stenosis was predilated with a 2.5-mm balloon. A 3.0ϫ18 mm Revision 1.1 ABSORB BVS (Figure 1 ) was deployed at 16 atm, and the scaffold was postdilated with a 3.25-mm noncompliant balloon at 24 atm (expected diameter, 3.5 mm). Although the angiographic appearances were good, there was malapposition of the proximal half of the scaffold shown by intravascular ultrasound (IVUS), and more clearly seen with optical coherence tomography (OCT) (Figure 1 ). After further inflations with a compliant 3.5-mm balloon to 16 atm (expected diameter, 4.0 mm), the angiographic appearances remained satisfactory. However, repeat IVUS and OCT showed persisting strut malapposition, including sections where the struts lay more centrally in the lumen, with strut overlap and loss of the typical strut pattern parallel to the vessel wall (Figures 2 and 3) .
The patient at discharge was medicated with aspirin and clopidogrel and was initially well but presented 1 month later with rest pain. Angiographic appearances remained satisfactory, but OCT revealed more extensive scaffold pattern disarray (Figures 2 and 3) . A 3.5ϫ18-mm everolimus-eluting metallic stent was successfully deployed within the same segment. One BVS strut was still protruding into the vessel lumen on OCT. Although it is not known whether a single fractured strut protruding into the lumen like a finger is associated with adverse outcomes, the operator chose to deploy a 3.5ϫ8-mm stent to remove this from the lumen. A bare metal stent was chosen to avoid multiple layers of drug-eluting struts. Final l angiographic and IVUS appearances were excellent ( Figure 2 ). The patient remains symptom-free18 months later.
This report demonstrates a limitation of early-generation bioresorbable polymeric scaffolds. There is a high likelihood of scaffold distortion and strut fracture if the current design of the 3.0-mm BVS scaffold is dilated beyond 3.5-mm diameter. Further strut displacement and disarray developed over the month after deployment. Although angiography revealed an apparently patent segment, IVUS and OCT appearances were consistent with strut rupture. Metallic stents were used to trap the polymeric struts against the vessel wall and to restore vessel scaffolding.
It is unclear what caused his rest pain at representation. It may have been secondary to disturbed coronary flow, microthrombus formation, and/or downstream vasospasm. The loss of vessel scaffolding, reduced drug delivery, and flow disturbance probably would predispose the lesion to stent thrombosis and restenosis.
Although changes in strut design and alteration in polymeric processing increase the vessel diameter working range and lessen the likelihood of strut rupture, bioresorbable polymeric scaffolds are less forgiving than metallic stents when overexpanded. Objective vessel sizing by on-line quantitative angiography or IVUS, after administration of intracoronary vasodilators, is recommended for accurate scaffold diameter selection.
Strut discontinuity and malapposition are not evident angiographically. Although IVUS provides some insights, the problem is best detected by OCT. These findings may have particular relevance as more complex lesions, for example, bifurcation stenoses, are treated. OCT may become an integral part of PCI procedures with bioresorbable scaffolds in these lesions. This case provides important insights to help guide the future safe and effective use of bioresorbable polymeric vascular scaffolds.
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